TC
OCUL icon

TFS Capital’s Ocular Therapeutix OCUL Stock Holding History

TFS Capital’s Portfolio OCUL Stock Details OCUL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-10,330
Closed -$217K – 1002
2015
Q2 		$217K Buy
+10,330
New +$256K 0.02% 737

Other funds holding OCUL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
SHI
SV Health Investors Boston, Massachusetts $32.3M AUM 20.15% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
LCP
Lamond Capital Partners San Francisco, California $14.3M AUM 30.74% 1-Year Est. Return
PVMCV
Polaris Venture Management Co V Boston, Massachusetts $14.1M AUM 121.41% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

TFS Capital's OCUL Position: Q3 2015 in Review

TFS Capital sold out of Ocular Therapeutix (OCUL) in Q3 2015, closing a stake of 10,330 shares — an estimated $217K sold.

TFS Capital first reported a position in OCUL in Q2 2015 and held it in 1 quarter. The position peaked at $217K in Q2 2015. 70 funds tracked by Wall St. Rank hold OCUL as of Q3 2015.

  • TFS Capital reported no remaining Ocular Therapeutix position as of Q3 2015 after selling out during the quarter.
  • TFS Capital sold 10,330 Ocular Therapeutix shares in Q3 2015, an estimated $217K.
  • TFS Capital first reported a position in Ocular Therapeutix in Q2 2015 and held it in 1 quarter.
  • TFS Capital's Ocular Therapeutix position peaked at $217K in Q2 2015.
  • 70 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q3 2015.

Based on TFS Capital's 13F filing for Q3 2015, filed 3 Nov 2015.